The Priority Review

Tag

Obrixtamig

1 story

  1. Clinical trials

    Boehringer Ingelheim registers Phase 3 safety rollover trial of obrixtamig in advanced cancer

    The study, first posted on ClinicalTrials.gov on November 10, 2026, plans to enroll 68 participants and begin in March 2027. It plans to find out how well participants who received obrixtamig in a previous study tolerate the drug.